What is the address of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE?

The registered office of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE is located at Rue Arthur Collier 29, 7021 Mons.

Is M.S. BOUQUEGNEAU-ENDOCRINOLOGIE still active?

Yes. According to the CBE (1 October 2026) M.S. BOUQUEGNEAU-ENDOCRINOLOGIE is active, legal situation “Normale toestand”, started on 18 February 2009.

Is M.S. BOUQUEGNEAU-ENDOCRINOLOGIE registered on Peppol?

Yes, M.S. BOUQUEGNEAU-ENDOCRINOLOGIE is registered on the Peppol network with ID 0208:0809954453.

What is the enterprise number of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE?

The enterprise number of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE is BE0809954453.

When was M.S. BOUQUEGNEAU-ENDOCRINOLOGIE founded?

M.S. BOUQUEGNEAU-ENDOCRINOLOGIE was founded on 18 February 2009.

Who are the directors of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE?

According to the 2025 annual accounts, the directors of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE are: Marie-Sylvie Bouquegneau.

Is M.S. BOUQUEGNEAU-ENDOCRINOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 February 2009; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did M.S. BOUQUEGNEAU-ENDOCRINOLOGIE make in 2025?

M.S. BOUQUEGNEAU-ENDOCRINOLOGIE posted a profit after taxes of € 32,485 in financial year 2025.

What is the revenue of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE?

As a small company, M.S. BOUQUEGNEAU-ENDOCRINOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 46,709.

M.S. BOUQUEGNEAU-ENDOCRINOLOGIE (Private Limited) - Mons

Dossier M.S. BOUQUEGNEAU-ENDOCRINOLOGIE, printed on 1 October 2026 from databakkes.be/en/0809954453/m-s-bouquegneau-endocrinologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

M.S. BOUQUEGNEAU-ENDOCRINOLOGIE from Mons, company number BE0809954453, closed financial year 2025 with a result of € 32,485 after tax. For that financial year M.S. BOUQUEGNEAU-ENDOCRINOLOGIE recorded a gross margin of € 46,709 and equity of € 89,727. Compared with financial year 2024, the result moved from € 31,994 to € 32,485. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 22, 2026.

What it is worth Growing

€ 89,727

▲ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 32,485

▲ 2% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 92,320

▼ 1% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 30,000 paid out

92 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 12,755

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 903

▲ 11% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 3,150

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 43,381 Gross margin 2022: € 43,381 First fiscal year in the series	€ 55,708 Gross margin 2023: € 55,708 ▲ 28% vs 2022 (€ 43,381) Favourable step	€ 43,284 Gross margin 2024: € 43,284 ▼ 22% vs 2023 (€ 55,708) Unfavourable step	€ 46,709 Gross margin 2025: € 46,709 ▲ 8% vs 2024 (€ 43,284) Favourable step	▲ 8%
Profit after taxes	€ 31,950 Profit after taxes 2022: € 31,950 First fiscal year in the series	€ 41,706 Profit after taxes 2023: € 41,706 ▲ 31% vs 2022 (€ 31,950) Favourable step	€ 31,994 Profit after taxes 2024: € 31,994 ▼ 23% vs 2023 (€ 41,706) Unfavourable step	€ 32,485 Profit after taxes 2025: € 32,485 ▲ 2% vs 2024 (€ 31,994) Favourable step	▲ 2%
Equity	€ 83,542 Equity 2022: € 83,542 First fiscal year in the series	€ 85,248 Equity 2023: € 85,248 ▲ 2% vs 2022 (€ 83,542) Favourable step	€ 87,242 Equity 2024: € 87,242 ▲ 2% vs 2023 (€ 85,248) Favourable step	€ 89,727 Equity 2025: € 89,727 ▲ 3% vs 2024 (€ 87,242) Favourable step	▲ 3%
Total debts	€ 32,608 Total debts 2022: € 32,608 First fiscal year in the series	€ 44,459 Total debts 2023: € 44,459 ▲ 36% vs 2022 (€ 32,608) Unfavourable step	€ 33,964 Total debts 2024: € 33,964 ▼ 24% vs 2023 (€ 44,459) Favourable step	€ 35,364 Total debts 2025: € 35,364 ▲ 4% vs 2024 (€ 33,964) Unfavourable step	▲ 4%
Cash	€ 104,717 Cash 2022: € 104,717 First fiscal year in the series	€ 116,096 Cash 2023: € 116,096 ▲ 11% vs 2022 (€ 104,717) Favourable step	€ 93,484 Cash 2024: € 93,484 ▼ 19% vs 2023 (€ 116,096) Unfavourable step	€ 92,320 Cash 2025: € 92,320 ▼ 1% vs 2024 (€ 93,484) Unfavourable step	▼ 1%
Retained profit	€ 71,092 Retained profit 2022: € 71,092 First fiscal year in the series	€ 72,798 Retained profit 2023: € 72,798 ▲ 2% vs 2022 (€ 71,092) Favourable step	€ 74,792 Retained profit 2024: € 74,792 ▲ 3% vs 2023 (€ 72,798) Favourable step	€ 77,277 Retained profit 2025: € 77,277 ▲ 3% vs 2024 (€ 74,792) Favourable step	▲ 3%
Dividend	€ 28,571 Dividend 2022: € 28,571 First fiscal year in the series	€ 40,000 Dividend 2023: € 40,000 ▲ 40% vs 2022 (€ 28,571) Unchanged	€ 30,000 Dividend 2024: € 30,000 ▼ 25% vs 2023 (€ 40,000) Unchanged	€ 30,000 Dividend 2025: € 30,000 Unchanged (€ 30,000) Unchanged
Balance sheet total	€ 116,150 Balance sheet total 2022: € 116,150 First fiscal year in the series	€ 129,706 Balance sheet total 2023: € 129,706 ▲ 12% vs 2022 (€ 116,150) Unchanged	€ 121,205 Balance sheet total 2024: € 121,205 ▼ 7% vs 2023 (€ 129,706) Unchanged	€ 125,091 Balance sheet total 2025: € 125,091 ▲ 3% vs 2024 (€ 121,205) Unchanged	▲ 3%

Key figures of M.S. BOUQUEGNEAU-ENDOCRINOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to M.S. BOUQUEGNEAU-ENDOCRINOLOGIE?

What happened at M.S. BOUQUEGNEAU-ENDOCRINOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 22, 2026 New annual accounts for financial year 2025: profit of € 32,485 (▲ 2% vs 2024). Source: NBB ↗
2023 Marie-Sylvie Bouquegneau became a director. NBB
Feb 18, 2009 New establishment in Mons. KBO
Feb 18, 2009 Start of the company according to the CBE. KBO

In short

From € 31,950 profit in 2022 to € 32,485 profit in 2025.

Paid € 36,862 in corporate taxes since 2022.

Best year ever: 2023, with € 41,706 profit.

Paid out € 128,571 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at M.S. BOUQUEGNEAU-ENDOCRINOLOGIE? We notify you, reason included.

Follow M.S. BOUQUEGNEAU-ENDOCRINOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Marie-Sylvie Bouquegneau

M.S. BOUQUEGNEAU-ENDOCRINOLOGIE

Behind M.S. BOUQUEGNEAU-ENDOCRINOLOGIE is Marie-Sylvie Bouquegneau.

See the full network in the app

Directors

According to the 2025 annual accounts

Marie-Sylvie Bouquegneau

Director

since 2023

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Arthur Collier 29

7021 Mons

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0809.954.453
VAT number: BE 0809.954.453
Registered office: Rue Arthur Collier 29, 7021 Mons
Names & denominations: M.S. BOUQUEGNEAU-ENDOCRINOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 18 February 2009
Peppol: Active · Active since 14 Jul 2025

View on CBE Public ↗ Annual accounts (NBB) ↗